BANGALORE, India, June 23, 2011 /PRNewswire/ —
Jubilant Biosys Ltd., Bengaluru, based subsidiary of Jubilant
Life Sciences Ltd., and AstraZeneca, today announced another
successful delivery of an early stage milestone in the Pain
therapeutic area.
The collaboration, initiated two years ago in the Neuroscience
therapeutic area, has now expanded to Cardiovascular and Metabolic
diseases and focuses on the delivery of a steady stream of
preclinical outcomes to AstraZeneca, by Jubilant. AstraZeneca owns
the compounds developed under the collaboration with worldwide
development and commercialization rights. Jubilant derives research
funding and success-based development and commercialization
milestones.
Commenting on this development,Sri Mosur, CEO &
President, Global Drug Discovery & Development, Jubilant
said: “We are pleased that we have delivered outcomes and early
success to the portfolio efforts at AstraZeneca. This is the
result of excellent collaboration between scientists at Jubilant
and AstraZeneca.
“Partnering is a strategic priority for AstraZeneca at all
stages of drug discovery and development,” says Christof Angst, CNS & Pain Innovative
Medicines, Vice-President, Strategy and Externalisation. “By
combining our strengths with those of our partners, we are in a
better position to deliver new medicines that can make a meaningful
difference to patients’ lives.”
About Us
Jubilant Biosys Ltd. is a Bengaluru based subsidiary of
Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant
Biosys, provides integrated drug discovery and development
solutions to the global pharmaceutical industry. It is a pioneer in
collaborative discovery research and development and is
engaged in multiple partnerships with global pharmaceutical
industry in therapeutic areas of Oncology, CNS and CVMED.
‘/>”/>
